Skip to main content

ESMO Highlights

Meeting Highlights

ESMO Highlights

Chemotherapy After Progression on Maintenance Olaparib in BRCA-Mutated Platinum-Sensitive Ovarian Cancer

Meeting Highlights

ESMO Highlights

A Network Meta-Analysis Comparing Efficacy of First-Line Maintenance PARP Inhibitors

Meeting Highlights

ESMO Highlights

Results from the GEICO1601-ROLANDO Phase 2 Trial Evaluating Combination of Olaparib and PLD in Platinum-Resistant Ovarian Cancer

Meeting Highlights

ESMO Highlights

Results of 5-Year Follow-Up of Maintenance Olaparib in Patients with Newly Diagnosed, Advanced Ovarian Cancer

Meeting Highlights

ESMO Highlights

Olaparib + Durvalumab and Bevacizumab: Initial Results in Patients with Non-Germline BRCA-Mutated Platinum-Sensitive Relapsed Ovarian Cancer

Meeting Highlights

ESMO Highlights

Phase 2 Trial of Olvi-Vec in Heavily Pretreated Platinum-Resistant/Refractory Ovarian Cancer

Meeting Highlights

ESMO Highlights

Efficacy and Safety of Niraparib in Older Patients with Advanced Ovarian Cancer from PRIMA/ENGOT-OV26/GOG-3012

Meeting Highlights

ESMO Highlights

Olaparib Maintenance Therapy in Clinical Practice: Quality-of-Life Interim Results of the C-PATROL Study in Ovarian Cancer

Meeting Highlights

ESMO Highlights

Response to Olaparib Monotherapy in Relapsed Ovarian Cancer by HRR Gene Mutational Status and HRD Scarring Analysis

Meeting Highlights

ESMO Highlights

Timing of Adverse Events During Maintenance Treatment with Rucaparib for Recurrent Ovarian Cancer in Phase 3 Study

1
2
3
4
5

Page 2 of 5
Results 11 - 20 of 44